The Pharmaceutical Market: Philippines

Date: January 31, 2013
Pages: 103
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P65BB6A6EE1EN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Philippines
THE PHARMACEUTICAL MARKET: PHILIPPINES - REVIEW

The Philippine economy expanded by an impressive 5.9% year-on-year in Q2 12 due to strong growth from various sectors, such as services and exports. Consequently, we have upgraded the pharmaceutical market forecast. We continue to hold our view that pharmaceutical firms will see short-term opportunities in the Philippines due to ineffective governance of the prices of drugs.

Headline Expenditure Projections

Pharmaceuticals: PHP126.04bn (US$2.91bn) in total sales in 2011, rising to PHP129.96bn (US$2.89bn) in 2012; +3.1% in local currency terms and +3.3% in US dollar terms. Forecast up slightly from Q 4 12 due to improved macroeconomic outlook .

Healthcare: PHP364.95bn (US$8.43bn) in sales in 2011 rising to PHP408.26bn (US$9.45bn) in 2012; +11.9% in local currency terms and +12.1% in US dollar terms. Forecast up slightly from Q 4 12 due to improved macroeconomic outlook .

Medical devices: PHP14.12bn (US$297mn) in sales in 2011 rising to PHP15.11bn (US$350mn) in 2012; +7.0% in local currency terms and +17.8% in US dollar terms. Forecast up slightly from Q 4 12 due to improved macroeconomic outlook.

Risk/Reward Rating:. This quarter, the Philippines retained a below-average score of 45.7 out of the maximum 100 points, placing it in14th position out of the 18 regional markets surveyed in Asia Pacific. On the whole, there is evidence that the market is maturing, with some sectors calling for the expansion of the socialised healthcare system to serve the entire nation. It is thought that such changes will boost volume consumption in particular.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

    Philippines Pharmaceutical And Healthcare Industry SWOT
    Philippines Political SWOT
    Philippines Economic SWOT
    Philippines Business Environment SWOT

PHARMACEUTICAL RISK/REWARD RATINGS

    Table: Asia Pacific Pharmaceutical Risk/Reward Ratings, Q113
    Rewards
    Risks

THE PHILIPPINES – MARKET SUMMARY

REGULATORY REGIME

    Table: History Of Food And Drugs Administration
    Regional Cooperation
    Cheaper Medicines Legislation
    Intellectual Property Regime
    IP Shortcomings
    IP Disputes
    Counterfeit Drugs
    Pricing Regime
    Pricing Developments
    Table: Medicines Subject To March 31 2010 Government Mediated Access Price
    Reimbursement Regime
    International Cooperation

INDUSTRY TRENDS AND DEVELOPMENTS

    Epidemiology
    Communicable Diseases
    Healthcare Sector
    Health Insurance
    Recent Health Insurance Developments
    Healthcare Sector Financing
    Medical Tourism
    Biotechnology and Research
    Biotechnology Developments
    Traditional Medicines
    Medical Devices

INDUSTRY FORECAST SCENARIO

    Overall Market Forecast
    Table: Pharmaceutical Sales Indicators 2008-2016
    Healthcare Market Forecast
    Table: Healthcare Expenditure Indicators 2008-2016
    Table: Healthcare Governmental Indicators 2008-2016
    Table: Healthcare Private Indicators 2008-2016
  Key Growth Factors – Macroeconomic
    Table: Philippines - Economic Activity
    Prescription Drug Market Forecast
    Table: Prescription Drug Sales Indicators 2008-2016
      Patented Drug Market Forecast
      Table: Patented Drug Market Indicators 2008-2016
      Generic Drug Market Forecast
      Table: Generic Drug Sales Indicators 2008-2016
      OTC Medicine Market Forecast
      Table: OTC Medicine Sales Indicators 2008-2016
      Pharmaceutical Trade Forecast
      Table: Exports and Imports Indicators 2008-2016
      Medical Device Market Forecast
      Table: Medical Devices Sales Indicators 2008-2016
      Other Healthcare Data Forecasts
      Key Risks To BMI’s Forecast Scenario

COMPETITIVE LANDSCAPE

      Pharmaceutical Industry
      Table: Pharmaceutical Industry Overview
      Domestic Pharmaceutical Industry
      Recent Pharmaceutical Industry Developments
      Pharmaceutical Distribution and Retail
  Distribution
  Retail
      Table: Overview Of BnB, BNB and P100 Programme
      Table: Cost Of Generic Drugs In Philippines (PHP)
      Table: Number Of BnBs and BNBs In Selected Philippine Regions

COMPANY MONITOR

  Local Companies
      Unilab
      Pascual Laboratories
      Pacific Pharma Generics
      MediChem Pharmaceuticals
  Multinational Companies
      GlaxoSmithKline Philippines
      Pfizer
      Novartis
      Merck & Co
      Sanofi

DEMOGRAPHIC OUTLOOK

      Table: Population By Age Group, 1990-2020 (‘000)
      Table: Population By Age Group, 1990-2020 (% of total)
      Table: Key Population Ratios, 1990-2020
      Table: Rural/Urban Population Split, 1990-2020

GLOSSARY

BMI METHODOLOGY

      How We Generate Our Pharmaceutical Industry Forecasts
      Risk/Reward Ratings Methodology
      Ratings Overview
      Table: Pharmaceutical Business Environment Indicators
      Weighting
      Table: Weighting Of Components
Skip to top


The Pharmaceutical Market: Cuba US$ 1,295.00 Mar, 2013
The Pharmaceutical Market: Czech Republic US$ 1,295.00 Jan, 2013 · 90 pages
The Pharmaceutical Market: Denmark US$ 1,295.00 Mar, 2013
The Pharmaceutical Market: Egypt US$ 1,295.00 Jan, 2013 · 111 pages

Ask Your Question

The Pharmaceutical Market: Philippines
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: